文献速递神经MRUS

帕金森病深部脑调控:DBS与低强度聚焦超声机制及转化分层

Deep-brain Neuromodulation in Parkinson's Disease: Convergent Mechanisms and Translational Stratification of Deep Brain Stimulation and Low-intensity Focused Ultrasound.
PubMed 文献 · Ultrasound Med Biol · 2026-08-18

本文为综述,从共同机制与转化视角比较深部脑刺激(DBS)与低强度聚焦超声(LIFUS)治疗帕金森病运动功能障碍。DBS临床证据成熟,LIFUS为较早期的无创平台,两者可能部分共享异常网络调控、突触与轴突重塑、神经炎症及α-突触核蛋白相关机制。

要点

  • DBS仍是帕金森病深部脑调控的临床基准,运动获益持久。
  • LIFUS可无创到达深部脑靶点,但临床证据仍有限。
  • 两者机制有部分重叠,证据深度和转化成熟度差异大。

核心结论

  • 深部脑调控应被视为多维治疗框架,而非孤立技术。

研究设计与样本

  • 本文为叙述性综述,讨论DBS与LIFUS在帕金森病中的共同机制与转化分层。

诊断标准与关键数值

  • DBS具有持久运动获益,机制框架已扩展至神经营养、蛋白病、神经免疫及自适应生物标志物引导层面。
  • LIFUS在炎症、凋亡、突触完整性和神经血管功能方面显示临床前效果。

局限性

  • LIFUS的临床证据仍然有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Parkinson's disease (PD) involves not only dopaminergic degeneration but also pathological changes in cortico-basal ganglia-thalamocortical circuits and broader disease-relevant biological processes. Deep-brain neuromodulation has emerged as an important therapeutic strategy for motor dysfunction. Among the available approaches, deep brain stimulation (DBS) is the most established modality, whereas low-intensity focused ultrasound (LIFUS), a form of transcranial ultrasound stimulation, represents a promising but earlier-stage, non-invasive platform. This review discusses DBS and LIFUS from a shared mechanistic and translational perspective. Current evidence suggests that the two modalities may engage partially overlapping mechanistic domains associated with motor deficit improvement, including modulation of abnormal network activity, promotion of synaptic and axonal remodeling, attenuation of neuroinflammation and cellular stress, and possible interaction with α-synuclein-related pathology. At the same time, they differ substantially in evidentiary depth, clinical maturity and translational readiness. DBS remains the clinical benchmark, with durable motor benefits and an expanding mechanistic framework that now extends beyond circuit correction to neurotrophic, proteinopathic, neuroimmune and adaptive biomarker-guided mechanisms. By contrast, LIFUS offers non-invasive access to deep brain targets and shows encouraging pre-clinical effects on inflammation, apoptosis, synaptic integrity and neurovascular function, but its clinical evidence remains limited. Overall, deep-brain neuromodulation in PD should be viewed as a multi-dimensional therapeutic framework rather than a group of isolated technologies. Future progress will depend on tighter integration of circuit physiology, pathology-relevant biomarkers, model selection and standardized translational endpoints.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Peng, Liu, Wang, et al. Deep-brain Neuromodulation in Parkinson's Disease: Convergent Mechanisms and Translational Stratification of Deep Brain Stimulation and Low-intensity Focused Ultrasound. Ultrasound Med Biol. 2026. PMID: 42608260. doi:10.1016/j.ultrasmedbio.2026.07.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。